Plasma cell leukaemia – Diagnostics – Overview of Information and Clinical Research

Plasma cell leukemia is a rare and aggressive blood cancer that requires prompt diagnosis to begin appropriate treatment. Understanding how doctors identify this condition and what tests are needed can help patients and families navigate the medical process more confidently.

Introduction: Who Should Undergo Diagnostics

Diagnosing plasma cell leukemia begins when a person develops symptoms that concern their healthcare provider or when routine blood tests show unusual results. People who should seek medical evaluation and potentially undergo diagnostics for plasma cell leukemia include those experiencing persistent symptoms that don’t have an obvious cause, such as ongoing fatigue, unexplained bone pain, frequent infections that keep returning, or easy bleeding and bruising.^[1]

It’s particularly important to seek diagnostics if you’ve been previously diagnosed with multiple myeloma, which is a related cancer of plasma cells. This is because plasma cell leukemia can develop as a transformation of existing multiple myeloma, known as secondary plasma cell leukemia. In these cases, regular monitoring and prompt evaluation of any new or worsening symptoms becomes crucial.^[7]

People who notice signs like unusual weakness, recurring fevers, or unexplained weight loss should also discuss these symptoms with their doctor. While these symptoms can be caused by many conditions, they warrant investigation, especially when they appear together or persist over time. Additionally, if you experience symptoms such as confusion, vision problems, or nerve-related issues like numbness or tingling, these could indicate that abnormal plasma cells are affecting different parts of your body and require immediate medical attention.^[3]

Healthcare providers may also recommend diagnostic testing for patients who have risk factors associated with plasma cell disorders. While the exact causes aren’t fully understood, plasma cell leukemia is more common in men between the ages of 55 and 65, and occurs more frequently among Black individuals. However, anyone experiencing concerning symptoms should seek evaluation regardless of their demographic profile.^[1]

Diagnostic Methods

The diagnosis of plasma cell leukemia relies on several key tests that work together to paint a complete picture of the disease. The cornerstone of diagnosis is measuring the number of abnormal plasma cells circulating in the blood. This differs from typical multiple myeloma, where abnormal plasma cells remain primarily in the bone marrow rather than entering the bloodstream.^[1]

Blood Tests

A standard blood test is the first and most critical diagnostic tool for plasma cell leukemia. Healthcare providers examine a sample of your blood under a microscope to count how many plasma cells are present and what percentage they represent of your total white blood cells. According to current medical understanding, if abnormal plasma cells make up more than 5% of your total white blood cells, this strongly suggests plasma cell leukemia. Previously, doctors used a threshold of 20%, but recent evidence shows that patients with lower levels of circulating plasma cells (as low as 5%) have the same poor prognosis, leading to updated diagnostic criteria.^[5]^[7]

Another measurement used in diagnosis is the absolute count of plasma cells in the blood. Historically, doctors looked for more than 2,000 plasma cells per microliter (or 2 × 10⁹ per liter) as an alternative diagnostic criterion. However, the percentage-based measurement has become more widely used, and having either criterion met can support the diagnosis.^[2]

Beyond counting plasma cells, blood tests also help identify other abnormalities associated with plasma cell leukemia. Doctors will check for anemia, which means low red blood cell counts, and thrombocytopenia, which refers to low platelet counts. These conditions are common in plasma cell leukemia because the abnormal cells interfere with normal blood cell production. Blood tests can also detect elevated levels of certain substances like lactate dehydrogenase and beta-2 microglobulin, which tend to be higher in patients with plasma cell leukemia compared to those with typical multiple myeloma.^[3]^[11]

Healthcare providers also test for abnormal proteins in the blood, called monoclonal proteins or myeloma proteins, which are produced by the malignant plasma cells. The type of protein present can vary—some patients have immunoglobulin G (IgG), others have IgA, some have only light chains, and a small percentage produce no detectable protein at all.^[3]

⚠️ Important

It’s crucial to distinguish plasma cell leukemia from reactive plasmacytosis, which is a temporary increase in plasma cells caused by infections, inflammatory conditions, or other non-cancerous causes. This is why doctors use additional tests beyond just counting plasma cells. Establishing that the plasma cells are clonal (all descended from a single abnormal cell) rather than reactive is an important part of accurate diagnosis.

Bone Marrow Biopsy

A bone marrow biopsy is another essential diagnostic procedure for plasma cell leukemia. During this test, a doctor removes a small sample of bone marrow, usually from the hip bone, using a special needle. The sample is then examined under a microscope to determine what percentage of cells in the bone marrow are abnormal plasma cells. This test helps doctors understand how extensively the disease has affected the bone marrow and provides additional information about the characteristics of the malignant cells.^[1]

The bone marrow biopsy also allows doctors to perform specialized tests on the cells, including genetic and molecular analyses. These tests can identify specific genetic abnormalities that are common in plasma cell leukemia and provide information about how aggressive the disease might be. Many patients with plasma cell leukemia have genetic changes typically found in advanced multiple myeloma, which helps explain why this disease behaves so aggressively.^[3]

Imaging Tests

Imaging studies play an important role in evaluating the extent of disease and identifying complications. Computed tomography scans, commonly known as CT scans, and magnetic resonance imaging (MRI) are used to check for bone damage that can result from plasma cell leukemia. These tests create detailed pictures of the inside of your body and can reveal areas where the abnormal cells have damaged bone or invaded other tissues.^[1]

Imaging is particularly valuable because plasma cell leukemia often causes different patterns of involvement compared to typical multiple myeloma. While multiple myeloma frequently causes specific bone lesions or fractures, plasma cell leukemia more commonly involves soft tissues and organs outside the bone marrow. Patients may develop enlarged liver or spleen, swollen lymph nodes, or deposits of malignant plasma cells in other organs, all of which can be detected through imaging studies.^[3]^[4]

Additional Laboratory Tests

Several other laboratory tests help doctors assess the impact of plasma cell leukemia on the body and guide treatment decisions. Kidney function tests are particularly important because plasma cell leukemia frequently causes kidney damage. Blood tests measuring calcium levels are also crucial, as many patients develop dangerously high calcium levels (hypercalcemia) due to bone breakdown. This can be a medical emergency requiring immediate treatment.^[1]^[4]

Doctors also check levels of various blood proteins and perform complete metabolic panels to assess overall organ function. Urine tests may be ordered to look for abnormal proteins being excreted by the kidneys, which can indicate kidney involvement and help predict potential complications.^[11]

Diagnostics for Clinical Trial Qualification

When patients with plasma cell leukemia consider participating in clinical trials, they typically need to undergo additional diagnostic procedures beyond the standard tests used for initial diagnosis. Clinical trials have specific criteria for patient enrollment, and comprehensive testing ensures that the trial includes appropriate participants who can safely receive the experimental treatment being studied.^[2]

Blood tests remain fundamental for clinical trial screening, but they’re often more detailed than routine diagnostic testing. Researchers need precise measurements of circulating plasma cells, not just to confirm the diagnosis but to establish a baseline for measuring how well the experimental treatment works. Trials may require specific thresholds for plasma cell percentages or absolute counts, and patients must meet these criteria to qualify.^[5]

Comprehensive genetic and molecular testing of plasma cells is increasingly required for clinical trial enrollment. Modern trials often target specific genetic abnormalities or molecular pathways, so patients need testing to determine whether their disease has the characteristics that the trial treatment is designed to address. This might include analysis for specific chromosome changes, gene mutations, or protein expression patterns. These sophisticated tests help match patients to trials where they’re most likely to benefit.^[2]

Organ function testing is another critical component of clinical trial qualification. Because experimental treatments can have unpredictable effects, trials typically require that patients have adequate kidney, liver, heart, and lung function before enrollment. This involves blood tests for kidney and liver function, heart tests like electrocardiograms (ECG or EKG) or echocardiograms (ultrasound of the heart), and sometimes lung function tests. These baseline assessments help ensure patient safety and allow researchers to monitor for treatment-related complications.^[6]

Bone marrow biopsies may need to be repeated for clinical trial qualification, even if a patient had one for initial diagnosis. Trials often have specific requirements about how recently the biopsy was performed and what information it must provide. Some trials require fresh samples for specialized testing that wasn’t available or necessary at initial diagnosis.^[2]

Imaging studies may also be required for trial enrollment and are used to establish baseline disease extent. This allows researchers to measure whether tumors or bone lesions shrink during treatment. Trials may specify particular types of imaging or require scans of specific body regions to comprehensively assess disease involvement.^[8]

⚠️ Important

Performance status assessment is a standard requirement for most clinical trials. This involves your doctor evaluating how well you can perform daily activities and how much the disease affects your physical functioning. Trials often exclude patients who are too sick to safely participate, though some trials specifically enroll patients with more advanced disease. Understanding these requirements helps patients and families have realistic expectations about trial eligibility.

Clinical trials may also require assessment of prior treatments received. For patients with secondary plasma cell leukemia who were previously treated for multiple myeloma, detailed documentation of all prior therapies, responses, and reasons for treatment changes is typically necessary. This information helps researchers understand how the disease has evolved and whether the patient is likely to respond to the trial treatment.^[6]

Some trials require evaluation for eligibility for stem cell transplantation, even if transplant isn’t part of the trial itself. This involves assessing overall health, age, organ function, and other medical conditions. Patients who might benefit from stem cell transplant may be directed toward trials that include transplant as part of the treatment strategy.^[6]

Prognosis and Survival Rate

Prognosis

The prognosis for plasma cell leukemia remains challenging despite advances in treatment. This disease is considered the most aggressive form of plasma cell disorders, with outcomes that are generally less favorable than those for typical multiple myeloma. Several factors affect how the disease progresses and what outcomes patients can expect. The type of plasma cell leukemia—whether primary (occurring without prior multiple myeloma) or secondary (developing from existing multiple myeloma)—significantly influences prognosis, with secondary cases typically having worse outcomes.^[9]

Certain disease characteristics at diagnosis help predict prognosis. Patients with higher levels of substances like lactate dehydrogenase or beta-2 microglobulin in their blood, those with severe anemia or very low platelet counts, and those with significant kidney damage tend to have more aggressive disease. The presence of specific genetic abnormalities also affects prognosis, with some chromosomal changes associated with particularly poor outcomes. Treatment response is another crucial factor—patients who achieve complete remission after initial treatment generally have better long-term outcomes than those with partial responses.^[3]^[8]

A patient’s overall health and ability to tolerate intensive treatment significantly impacts prognosis. Younger, healthier patients who can undergo aggressive therapy including stem cell transplantation typically have better outcomes than older or frailer patients who can only receive less intensive treatments. The availability of maintenance therapy after initial treatment also appears to improve long-term outcomes for some patients.^[8]

Despite treatment advances, plasma cell leukemia typically cannot be cured with current therapies. However, treatment can slow disease progression, manage symptoms, and prolong life. The introduction of novel agents like proteasome inhibitors and immunomodulatory drugs has improved outcomes compared to older chemotherapy approaches, though the gains have been more modest than those seen in multiple myeloma. Newer treatments including monoclonal antibodies and cellular therapies offer hope for further improvement in the future.^[1]^[9]

Survival Rate

Survival statistics for plasma cell leukemia have improved over recent decades, but the disease remains life-threatening. For primary plasma cell leukemia, median overall survival has historically been reported as approximately 7 months with conventional chemotherapy alone. However, with modern treatment approaches incorporating novel agents and stem cell transplantation for eligible patients, survival has improved considerably.^[11]

Recent studies show that median overall survival for patients receiving contemporary treatments ranges from approximately one year for older patients who cannot undergo transplant to about three years for younger patients who receive stem cell transplantation after initial therapy. Some reports indicate median survival approaching 33 months when all patients are considered together. However, these figures represent averages, and individual outcomes vary widely based on disease characteristics and treatment response.^[1]^[8]

Progression-free survival, which measures how long patients remain in remission without disease worsening, is typically shorter than overall survival. Studies report median progression-free survival ranging from approximately 12 to 14 months with modern treatments. This indicates that while treatments can often control the disease initially, relapse remains common and usually occurs within the first year or two after treatment.^[8]

Secondary plasma cell leukemia, which develops from pre-existing multiple myeloma, generally has an even more guarded prognosis than primary disease. Because these patients have already received multiple treatments for their myeloma, the leukemic cells are often resistant to many available therapies, making effective treatment more challenging. Survival for secondary plasma cell leukemia is typically measured in months rather than years, though outcomes vary based on which treatments remain available and how aggressive the leukemic transformation is.^[9]

It’s important to understand that survival statistics are based on groups of patients and cannot predict what will happen to any individual. Some patients live considerably longer than average, particularly those whose disease responds well to treatment and who remain healthy enough to receive multiple lines of therapy. Ongoing research continues to identify new treatments that may further improve survival in the future.^[2]

#1 Clinical Trials Search in Europe